”We found that people with lactose intolerance, who typically consume low amounts of milk and other dairy products, have a reduced risk of lung, breast and ovarian cancers”, says Jianguang Ji, Associate Professor at Lund University and researcher at the Center for Primary Care Research in Malmö.
”The risk of cancer was not reduced in relatives of people with lactose intolerance, which indicates that protection against these cancers is related to diet. However, it would be wrong to conclude that milk is a risk factor for these cancers”, emphasises Jianguang Ji.
There are large differences in the incidence of breast and ovarian cancers between different countries. Their incidence is highest in North America, Western Europe and the Nordic countries, and lowest in East Asia and Central African countries. Studies of immigrants and twins suggest this worldwide variation is more down to environmental factors than to genetic or ethnic factors.
Lifestyle factors such as high consumption of milk and other dairy products have been suspected to contribute to the high incidence of breast and ovarian cancers in North America and Western Europe. However, previous studies are inconclusive. One recent review by the World Cancer Research Fund and the American Institute of Cancer Research found a lack of evidence linking consumption of dairy products to breast cancer risk.
”In order to investigate this unanswered question we adopted a novel approach”, says Jianguang Ji. ”We investigated whether low consumption of milk and other dairy products protects lactose-intolerant people against breast and ovarian cancers. Since epidemiological and animal studies show that milk consumption and lung cancer risk are both associated with the protein IGF-1 (insulin like growth factor 1), we also investigated lung cancer.”
”Using nationwide data from two Swedish registers (the Inpatient Register and the Outpatient Register) we identified 22,788 individuals with lactose intolerance and examined their risk of suffering from lung, breast and ovarian cancers. The risks of lung cancer (standardised incidence ratio [SIR] = 0.55), breast cancer (SIR = 0.79) and ovarian cancer (SIR = 0.55) were significantly lower in people with lactose intolerance compared to people without lactose intolerance, irrespective of country of birth and gender”, explains Jianguang Ji. ”By contrast, the risks in their siblings and parents were the same as in the general population. This suggests that the lower cancer risk in people with lactose intolerance may be due to their diet.”
Factors such as lower calorie intake of because of low milk consumption and protective factors in plant-based milk drinks may contribute to the observed negative association between lactose intolerance and the studied cancers.
”We must interpret these results with caution because the association we found is insufficient to conclude a causative effect”, emphasises Jianguang Ji. ”Further studies are needed to identify factors that explain the study’s results.”
‘Lactose intolerance and risk of lung, breast and ovarian cancers: aetiological clues from a population-based study in Sweden’ (Jianguang Ji, Jan Sundquist, Kristina Sundquist), British Journal of Cancer
Associate Professor Jianguang Ji, MD, PhD
The Center for Primary Health Care Research is a collaboration between Lund University (situated in Skåne, the southernmost county in Sweden) and Region Skåne (the county council in Skåne).
Lund University was founded in 1666 and is ranked as one of the top 100 universities in the world. With high-quality education and research at eight faculties, we are one of the most comprehensive universities in Scandinavia. The University has 47000 students and 7000 staff based in Lund, Helsingborg and Malmö. Lund is often considered to be Sweden’s most attractive study destination and huge investments are currently being made in the new research facilities MAX IV and ESS in the city.
Barbara Jacoby is an award winning blogger that has contributed her writings to multiple online publications that have touched readers worldwide.